Medtronic stock trades 27% below our $112 truthful benefit estimate. The largest pure-play clinical-system maker is often a essential lover for its medical center prospects, thanks to its diversified product portfolio aimed toward a wide range of Serious illnesses, Morningstar senior analyst Debbie Wang describes. Medtronic has raised its dividend